Farletuzumab ecteribulin is an antibody-drug conjugate (ADC) that targets the folate receptor alpha (FRA) using the humanized anti-FRA antibody Farletuzumab. Conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin, this compound features an agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin exhibits significant cytotoxicity towards FRA-positive cancer cells and demonstrates potent antitumor activity, making it a valuable reagent for research in targeted cancer therapies.
Farletuzumab ecteribulin is an antibody-drug conjugate (ADC) that targets the folate receptor alpha (FRA) using the humanized anti-FRA antibody Farletuzumab. Conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin, this compound features an agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin exhibits significant cytotoxicity towards FRA-positive cancer cells and demonstrates potent antitumor activity, making it a valuable reagent for research in targeted cancer therapies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
